Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 13/20 | 0.46 |
| ▸ | PTK2B | Q14289 | 10/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.46 |
| ▸ | NEK2 | P51955 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | BCL6 | P41182 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668635 | 0.97 | PTK2 (0.46) | PTK2PTK2BTBK1NEK2PLK1 | |
| SCHEMBL670533 | 0.90 | PTK2 (0.53) | PTK2PTK2BTBK1NEK2BCL6 | |
| SCHEMBL15023744 | 0.89 | PTK2B (0.49) | PTK2PTK2BTBK1PLK1GABRA1 | |
| SCHEMBL669843 | 0.86 | PTK2B (0.49) | PTK2PTK2BTBK1PLK1GABRA1 | |
| SCHEMBL10125382 | 0.85 | TBK1 (0.45) | PTK2PTK2BTBK1NEK2PLK1 | |
| SCHEMBL10125761 | 0.85 | TBK1 (0.45) | PTK2PTK2BTBK1NEK2PLK1 | |
| SCHEMBL10125762 | 0.78 | PTK2B (0.51) | PTK2PTK2BTBK1PLK1BCL6 | |
| SCHEMBL670549 | 0.77 | PTK2 (0.49) | PTK2PTK2BTBK1NEK2BCL6 | |
| SCHEMBL670009 | 0.77 | PTK2 (0.49) | PTK2PTK2BTBK1NEK2BCL6 | |
| SCHEMBL15023735 | 0.76 | PTK2B (0.46) | PTK2PTK2BTBK1NEK2PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606034-B1 | PYRIMIDINE DERIVATIVE AS FAK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-03-09 | — | — | EP | claimed |
| US-8906916-B2 | Pyrimidine derivatives as FAK inhibitors | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | claimed |
| US-20130158005-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-20 | — | — | US | claimed |
| EP-2606034-B1 | PYRIMIDINE DERIVATIVE AS FAK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-03-09 | — | — | EP | disclosed |
| EP-2606034-B1 | PYRIMIDINE DERIVATIVE AS FAK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-8906916-B2 | Pyrimidine derivatives as FAK inhibitors | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8906916-B2 | Pyrimidine derivatives as FAK inhibitors | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-20130158005-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158005-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-20 | — | — | US | disclosed |
| WO-2012022408-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | MERCK PATENT GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158005-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | CDK2, PTK2, CDKN1A | PTK2 2/4885PTK2B 21/4885TBK1 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.